Market Research Logo

Antibody Drug Conjugates Market 3rd Edition, 2015 - 2025

Antibody Drug Conjugates Market 3rd Edition, 2015 - 2025

The ADC market is being driven by the sales of ADCETRIS® and KADCYLA®, the only two commercially available drugs. It is a relatively new concept with respect to technology, although the individual molecules that form ADCs have been used since long. This new class of therapeutics has witnessed a strong acceptance from both big and small pharmaceutical companies as they try to fill gaps in their respective oncology pipelines. There has been a healthy growth in the number of pipeline molecules (both clinical and preclinical), suggesting a heavy focus of stakeholders in the industry. Majority of the drugs are being developed for oncological indications. In fact, several molecules are designed to target a large bandwidth of cancers, focussing on multiple indications; such molecules form 19% of the clinical pipeline.

The field has been abuzz with partnering activities; such collaborations provide a synergistic boom to both the partners in terms of enrichment of product portfolio, revenues and stability. Technology licensing is the preferred model for ADC development. Seattle Genetics and ImmunoGen, the two leading technology developers, have been involved in a number of partnerships. In fact, a significant proportion of ADCs in development are based on the ADC technology of these two companies.

The unexploited and promising nature of this market supports the hopes pinned on multiple start-ups by several strategic investors and venture capital firms. Over 80 instances of funding (equity + debt) were traced during our research, with the total investment amounting to an encouraging sum of USD 1.9 billion over the last decade. In addition to the venture capital firms, big pharma companies have also made strategic investment in smaller companies focused on developing ADCs.

A rich pipeline, promising safety / efficacy results and strong backing by venture capital firms is likely to result in a significant growth in the market over the next ten years. In the longer term, several start-ups / university spin-offs, which currently have molecules in preclinical / discovery phase, are expected to sustain the growth momentum.

SCOPE OF THE REPORT
The “Antibody Drug Conjugates Market (3rd edition), 2015-2025” report provides a comprehensive analysis of the current market landscape and future outlook of the growing pipeline of ADCs. The ADC market has been one of the most actively evolving markets over the last few years and encompasses a myriad of therapies that can be potentially exploited for a broad range of cancer indications.

One of the key objectives of the study is to review and quantify the opportunities laid by the robust, opportunistic and broad pipelines of the pharmaceutical firms. With two marketed drugs (ADCETRIS® and KADCYLA®), the market is treading its way towards fulfilling a huge untapped promise. Amongst other elements, the report elaborates on the following key areas:
The current state of the market with respect to key players, developmental stage of pipeline products (both clinical / pre-clinical) and indications targeted
Technology providers, and key cytotoxin, linker and conjugation technologies supporting the development of improved ADCs
Recent partnerships that have taken place over the last decade including product co-development, licensing and clinical trial collaborations
Various investments and grants received by the companies focused in this area
Therapeutic areas forming the current focus of developers, the gradual drift and expansion towards broader application areas
Competitive landscape and inherent threats to growth in the short and long term
Development and sales potential, based on target consumer segments, likely adoption rate and expected pricing, of molecules in late stages of development

The base year for the report is 2015. The report provides market forecast for the period 2015-2025. The research, analysis and insights presented in this report include potential sales of several ADCs; this analysis is backed by a deep understanding of key drivers behind the growth.

Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry’s evolution. All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. Driven by the sales of ADCETRIS® and KADCYLA® (the only two drugs currently available commercially), the ADC market is estimated to be worth around USD 0.9 billion in 2015.
2. The market has a strong clinical pipeline of 53 molecules; nearly one-third of the molecules are in Phase II or Phase III of development. The dynamic pipeline also includes a number of molecules in preclinical/ discovery stage; in our research, we came across over 60 such molecules.
3. Most commonly used cytotoxins for ADCs under clinical development include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin dominates the market and accounts for over 50% of ADCs in clinical development.
4. Roche, with six molecules in clinical development, has the most developed pipeline of ADCs. Other established players in the market are (in alphabetical order) AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BMS, GSK, Novartis, Pfizer and Sanofi.
5. Relative new entrants include (in alphabetical order) AbGenomics, Allozyne, Ambrx, Biotest, Celldex Therapeutics, Centrose, CytomX Therapeutics, Esperance Pharmaceuticals, Formation Biologics, Genmab, Heidelberg Pharma, Igenica, Immunomedics, Oxford BioTherapeutics, Kairos Therapeutics, Merrimack Pharmaceuticals, Mersana Therapeutics, NBE Therapeutics, Philochem, PhotoBiotics, Progenics Pharmaceuticals, Sorrento Therapeutics, Stem CentRx, Sutro Biopharma, Synthon, Zymeworks; emergence of these firms is likely to provide the necessary push, both in terms of technology and innovation.
6. About 70%-80% of ADC manufacturing is currently outsourced. There are limited number of contract manufacturers with capabilities for development of linkers and cytotoxins. In addition, even fewer CMOs provide conjugation services for ADC.
7. Several technological developments have taken place in the recent past; more stable linkers and potent cytotoxins are likely to ensure that the next generation ADCs have improved safety / efficacy profile.
8. With around 10 new ADC commercial launches over the coming decade, we believe the overall market will be worth USD 10 billion annually by 2025. Favourable market environment and regulatory regimes could result in an even steeper growth.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 presents an executive summary of the report. It offers a high level view on where the ADC market is headed in the mid-long term.
Chapter 3 provides a general introduction to the ADCs. In this section, we have discussed, in detail, the concept of ADC, its components, mechanism of action and advantages over traditional therapies.

Chapter 4 provides a comprehensive landscape of the ADC market. This chapter has information on all the ADC molecules in development (clinical and preclinical) along with their current phase of development, key targeted indications, companies that are active in the field of ADC and most common types of cytotoxins and linkers used for ADC development.

Chapter 5 provides our analysis of the key opinion leaders (KOLs) focused in the ADC research sector. It provides a comprehensive list of principal investigators, along with their respective research institutes, and highlights KOLs who have relatively more experience.

Chapter 6 provides a competitive portfolio of various therapies being developed for the treatment of commonly targeted indications. These indications have been the prime focus of companies developing ADCs. The chapter also highlights the epidemiological facts and currently available treatment options for each indication.

Chapter 7 presents our analysis on the ADC market opportunity in the upcoming decade. It includes detailed drug profiles and likely sales forecast for drugs currently in phase II or higher stage of development. The profiles cover information such as drug’s mechanism of action, history of development, clinical trial timeline, clinical trial results, manufacturing, estimated cost of treatment and dosage regimen.

Chapter 8 provides a comprehensive list of partnerships, including the details of agreements, which have taken place between various companies over the last few years.

Chapter 9 provides information on several funding instances that have driven research and development in the field of ADCs. Our analysis reveals interesting insights on the growing interest of venture capitalists and other stakeholders in this market.

Chapter 10 includes profiles of the key companies focused in the ADC market. Each company profile includes information such as financial performance, geographical presence, marketed / pipeline ADC drugs and recent collaborations.

Chapter 11 presents a case study on ADC manufacturing. The case study discusses the current manufacturing challenges associated with ADCs and provides information on the leading contract manufacturers that are focused in this domain.

Chapter 12 provides our analysis of the strengths, weaknesses, opportunities and threats in the ADC market, capturing the key elements likely to influence future growth.

Chapter 13 is a collection of interview transcripts; these discussions have helped us in forming a better understanding of the key market dynamics, competitive landscape and the likely future trends in the market. The companies interviewed include Piramal Healthcare, Pierre Fabre, PolyTherics, Oxford BioTherapeutics, Lonza, Catalent Pharma Solutions and BSP Pharmaceuticals. Two additional companies that were interviewed requested the details to be published as anonymous.

Chapter 14 summarises the overall report. In this chapter, we have provided a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which lists down all the companies and organisations involved in the ADC market.

LIST OF COMPANIES AND ORGANISATIONS

Following companies, hospitals, institutes / universities and organisations have been mentioned in this report.
1. AAIPharma Services Corp
2. AB SCIEX
3. AbbVie
4. AbGenomics
5. Abramson Cancer Center of the University of Pennsylvania
6. Abraxis BioScience
7. Academic and Community Cancer Research United
8. Academic Medical Center, University of Amsterdam
9. ACES Pharma
10. ADC Therapeutics
11. Adimab
12. Affinity Lifesciences
13. Agensys
14. AIDS Malignancy Consortium
15. Algeta
16. Allos Therapeutics
17. Allozyne
18. ALMAC Group
19. Ambrx
20. American Cancer Society
21. American Society of Clinical Oncology (ASCO)
22. American Society of Haematology, San Francisco
23. AmerisourceBergen Corporation
24. Amgen
25. AMRI Global
26. Asan Medical Center
27. Aspyrian Therapeutics
28. Astellas Pharma
29. AstraZeneca
30. Asymchem
31. Avid Biologics
32. Bachem
33. Barbara Ann Karmanos Cancer Institute
34. Baxter BioPharma Solutions
35. Bayer Healthcare
36. Beatson West of Scotland Cancer Center
37. BioAgilytix Labs
38. Biogen Idec
39. BioOutsource
40. BioPharma Solutions
41. Biotechnique
42. Biotecnol
43. Biotest
44. BioWa
45. Boehringer Ingelheim
46. Bristol-Myers Squibb
47. Brown University
48. BSP Pharmaceuticals
49. Cambrex Corporation
50. Cancer Institute of Lorraine
51. Cancer Research Technology (CRT), UK
52. Cancer Research, UK
53. Cancer Treatment Centers of America
54. Cantonal Hospital of St. Gallen
55. CARBOGEN AMCIS
56. Cardinal Health
57. Catalent Pharma Solution
58. Celgene
59. Celldex Therapeutics
60. Centers for Disease Control and Prevention
61. Centre Hospitalier Lyon Sud, France
62. Centre Oscar Lambret
63. Centrose
64. ChemCon
65. ChemPartner
66. Children's Oncology Group
67. Chu de Limoges
68. Chugai Pharmaceutical
69. City of Hope Medical Center
70. CMC Biologics
71. Coldstream Laboratories
72. Columbia University
73. Concortis
74. Creative Biolabs
75. CuraGen
76. Cytogen Corporation
77. CytomX Therapeutics
78. Cytovance Biologics LLC
79. Daiichi Sankyo
80. Dalton Pharma Services
81. Dana-Farber Cancer Institute
82. Dendreon Corporation
83. Dishman Group
84. ECOG-ACRIN Cancer Research Group
85. EirGenix
86. Eisai
87. Elder Pharmaceuticals
88. Eli Lilly
89. Endo Pharmaceuticals
90. Endocyte
91. Esperance Pharmaceuticals
92. Eucodis
93. European Organisation for Research and Treatment of Cancer
94. Evonik
95. Ferring Pharmaceuticals
96. Ferro Pfanstiehl
97. Fidelity Biosciences
98. Formation Biologics
99. Formosa Laboratories
100. Fox Chase Cancer Center
101. FUJIFILM Diosynth Biotechnologies
102. Genentech
103. General Hospital Linz
104. Genmab
105. Genzyme
106. German Federal Ministry of Education and Research
107. Gilead Sciences
108. GLOBOCAN
109. Goodwin Biotechnology
110. GSK
111. GTC Biotherapeutics
112. Guys Hospital
113. H. Lee Moffitt Cancer Center & Research Institute Dept of Onc
114. Harris and Harris Group
115. Hartmann Oncology Radiotherapy Group
116. Heidelberg Pharma
117. Heraeus
118. Hospital Ramon y Cajal, Madrid, Spain
119. Hospital Saint-Louis
120. Hospital Universitario de Salamanca
121. iBIOSOURCE
122. ICM
123. IDT Australia
124. Igenica
125. ImClone Systems
126. Immunogen
127. Immunomedics
128. INC Research
129. Innsbruck Medical University
130. Institut Bergonié, Bordeaux
131. Institut Curie
132. Invenra
133. IRCCS AOU San Martino
134. IUHealth Goshen Center for Cancer Care
135. Janssen Biotech
136. Johnson & Johnson
137. Jules Bordet Institute
138. Kairos Therapeutics
139. Karolinska university hospital
140. Kemwell
141. Korea Cancer Center Hospital
142. Leica Biosystems
143. Leukaemia and Lymphoma Society
144. Life Science Pharmaceuticals
145. Ligand Pharmaceuticals
146. Lonza
147. Lymphoma Study Association
148. M D Anderson Cancer Center
149. MAB Discovery
150. MacroGenics
151. Massachusetts General Hospital
152. Mayo Clinic
153. McKesson Corporation
154. Medarex
155. Medical College of Wisconsin
156. Medical University of Vienna
157. MedImmune
158. Medivation
159. MedStar Washington Hospital Center
160. Memorial Sloan-Kettering Cancer Center
161. Menarini
162. Merck
163. Merrimack Pharmaceuticals
164. Mersana Therapeutics
165. Millenium Pharmaceuticals
166. MiMabs
167. Molecular Insight Pharmaceuticals
168. Morphotek
169. Natco Pharma
170. National Cancer Center of Korea
171. National Cancer Institute
172. National Research Council of Canada
173. NBE Therapeutics
174. New Enterprise Associates
175. New York Medical College
176. Nordic Nanovector
177. Norfolk and Norwich Hospital
178. Northwestern University
179. Nottingham University Hospitals NHS Trust
180. Novartis
181. Novasep
182. Novella Clinical
183. NSABP Foundation
184. Ohio State University
185. Oncology Institute of Southern Switzerland
186. Oncology-Rinat Research and Development (ORRD)
187. Ono Pharmaceutical
188. Onyx Pharmaceuticals
189. Oslo University Hospital
190. Oxford BioTherapeutics
191. Pacific GMP
192. Patheon
193. Pfizer
194. Pharmacyclics
195. Philochem
196. Philogen
197. PhotoBiotics
198. Pierre Fabre Group
199. Piramal Pharma Solutions
200. PolyTherics
201. Princess Margaret Hospital
202. Progenics Pharmaceuticals
203. Project Pharmaceutics
204. ProQuest Investments
205. PureTech Ventures
206. QPS Holdings
207. Quanta BioDesign
208. Queen Elizabeth Hospital
209. Recepta Biopharma
210. Redwood Bioscience
211. Regional Center for the Fight Against Cancer
212. Roche
213. Royal Liverpool Hospital
214. S. Orsola Malpighi
215. SAFC
216. SafeBridge Consultants
217. Sandoz
218. Sanofi
219. Sarah Cannon Research Institute
220. SCRI Innovations
221. Seattle Genetics
222. Seoul National University Hospital
223. Seragon Pharmaceuticals
224. Severance Hospital
225. Shanghai Fosun Pharma
226. Sigma-Aldrich Corporation
227. Societa Italiana Corticosteroidi
228. Society for Neuro-Oncology (SNO), Miami
229. Sorrento Therapeutics
230. Southampton General Hospital
231. Southwest Oncology Group
232. Spectrum Pharmaceuticals
233. Spirogen
234. St James University Hospital
235. St. Jude Children's Research Hospital
236. Stem CentRx
237. Sutro Biopharma
238. Symbiosis Pharmaceutical Services
239. Syntarga
240. Synthon
241. Takeda Pharmaceutical
242. The Chemistry Research Solution
243. The Christie Hospital
244. The Churchill Hospital,UK
245. The Freeman Hospital
246. The Institute of Haematology in Bologna
247. The Methodist Hospital System
248. Tuas Biomedical Park
249. TUBE Pharma
250. UCB Pharma
251. UCL School of Pharmacy
252. UCLA Jonsson Comprehensive Cancer Center
253. Union Chimique Belge
254. University Hospital of Wales
255. University Hospital, UK
256. University Hospitals Seidman Cancer Center
257. University of Alabama
258. University of Amsterdam
259. University of California
260. University of Cologne
261. University of Kansas Medical Center Research Institute
262. University of Modena and Reggio Emilia
263. University of Munich
264. University of Oklahoma Stephenson Cancer Center
265. University of Texas Health Science Center
266. University of Ulm
267. University of Washington Cancer Consortium
268. UT Southwestern Medical Center
269. UZ Leuven Hospital
270. Valeant Pharmaceutical
271. Vanderbilt-Ingram Cancer Center
272. Ventana Medical Systems
273. Victor Hugo Surgical Clinic
274. Virginia Cancer Specialists, PC
275. VivaMab
276. Washington University School of Medicine
277. Waters
278. Watson Pharmaceuticals
279. Weill Medical College of Cornell University
280. Western Regional Medical Center
281. WILEX
282. WuXi PharmaTech
283. Wyeth
284. Zhejiang Medicine Co. (ZMC)
285. Zymeworks

Following venture capital firms / investors have been mentioned in this report.
1. 5AM Ventures
2. Advanced Biotechnologies Venture Fund
3. Advantage Capital Partners
4. Advent Venture Partners
5. Alexandria Real Estate Equities
6. Alta Partners
7. Amgen Ventures
8. Apax Partner
9. Apposite Capital
10. Aravis Ventures
11. ARCH Venture Partners
12. Auven Therapeutics
13. BankInvest Group
14. Bear Sterns Health Innoventures
15. Boehringer Ingelheim Venture Fund
16. BSI
17. Canaan Partners
18. Carnegie Kapitalforvaltning
19. Cascade Investment
20. Casdin Capital
21. Catapult Ventures
22. Cooley Godward Kronish
23. Cormorant Asset Management
24. Credit Suisse First Boston Next Fund
25. Crocker Ventures
26. CTI Life Sciences Fund
27. Dansk Erhvervsinvestering
28. Deerfield Management
29. Dow Venture Capital
30. Duquesne Capital Management
31. Expansion Venture Capital
32. Fidelity Investments
33. Fred Alger Management
34. Glynn Capital Management
35. H&Q Life Sciences Investments
36. Hambrecht & Quist Capital Management
37. HBM BioVentures
38. HBM Partners
39. HealthCap Venture Capital
40. Hercules Technology Growth Capital
41. HNI Holdings
42. Index Ventures
43. Innovis Investments
44. International Biotechnology Trust
45. Iroquois Capital Group
46. JAFCO
47. Jennison Associates
48. Lilly Ventures
49. LODH Private Equity Partners
50. Lombard Odier Darier Hentsch & Cie
51. Maverick Capital
52. Modal Capital L.P.
53. MPM Capital
54. MS Seed Capital
55. MS Ventures
56. Nextech Venture
57. Noonday Asset Management
58. Orbimed Advisors
59. OVP Venture Partners
60. Oxford Capital Partners
61. Perceptive Advisors
62. Pfizer Venture Investments
63. Presidio Partners
64. Redmile Group
65. ReqMed Company
66. Research Corporation Technologies
67. Roche Venture Fund
68. Scale Venture Partners
69. Scottish Widows Investment Partnership
70. Silicon Valley Bank
71. Skyline Ventures
72. Sofinnova Ventures
73. Sorenson Development
74. South East Growth Fund & Management
75. Suez Ventures
76. SV Life Sciences
77. Tavistock Life Sciences
78. Tekla Healthcare investors & Tekla Life Science Investors
79. The Column Group
80. Themelios Ventures
81. Third Rock Ventures
82. TPG-Axon Capital
83. Twilight Venture Partners
84. Unilever Technology Ventures Fund B.V.
85. Union Carbide Employees Pension Plan
86. Venrock Healthcare Capital Partners
87. Venture Associates
88. Ventures West Capital
89. Versant Ventures
90. VLG Investments
91. Vulcan Capital
92. Wellington Management Company
93. Wharton Biotechnology Partners
94. WT Investment Advisors Fund
95. Ziff Asset Management
96. Zroche Venture Fund


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Cancer Treatment
3.3. Cancer Treatment Methods
3.3.1. Surgery
3.3.2. Radiation Therapy
3.3.3. Chemotherapy
3.3.4. Targeted Therapies
3.4. Monoclonal Antibodies to Treat Cancer
3.5. ADCs: Essential Components
3.5.1. Antibody
3.5.2. Cytotoxin
3.5.3. Linker
3.6. Advantages of ADCs Over Traditional Therapeutics
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Clinical Pipeline
4.2.1. Distribution by Phases of Development
4.2.2. Distribution by Indications
4.2.3. Distribution by Linkers
4.2.4. Distribution by Cytotoxins
4.2.5. Distribution by Technology Providers
4.3. Preclinical Pipeline
4.3.1. Distribution by Phases of Development
4.3.2. Distribution by Indications
4.3.3. Distribution by Geographies
5. KOL ANALYSIS
5.1. Background
5.2. Current Research Landscape
5.2.1. ADCETRIS®: Key Opinion Leaders
5.2.2. KADCYLA®: Key Opinion Leaders
5.2.3. Other ADCs: Key Opinion Leaders
5.3. Most Prominent Key Opinion Leaders
6. KEY THERAPEUTIC AREAS FOR ADCS
6.1. Chapter Overview
6.2. Haematological Malignancies
6.2.1. Leukaemia and Lymphoma
6.2.1.1. Introduction and Epidemiology: Leukaemia
6.2.1.1.1. Acute Myeloid Leukaemia (AML)
6.2.1.1.2. Chronic Myeloid Leukaemia (CML)
6.2.1.1.3. Acute Lymphocytic Leukaemia (ALL)
6.2.1.1.4. Chronic Lymphocytic Leukaemia (CLL)
6.2.1.2. Introduction and Epidemiology: Lymphoma
6.2.1.3. Current Treatment Landscape
6.2.1.3.1. Targeted Therapies
6.2.1.4. ADCs for Leukaemia/Lymphoma
6.2.2. Multiple Myeloma
6.2.2.1. Introduction and Epidemiology
6.2.2.2. Current Treatment Landscape
6.2.2.3. ADCs for Multiple Myeloma
6.3. Solid Tumours
6.3.1. Metastatic Melanoma
6.3.1.1. Introduction and Epidemiology
6.3.1.2. Current Treatment Landscape
6.3.1.3. ADCs for Metastatic Melanoma
6.3.2. Bladder Cancer
6.3.2.1. Introduction and Epidemiology
6.3.2.2. Current Treatment Landscape
6.3.2.3. ADCs For Bladder Cancer
6.3.3. Kidney Cancer
6.3.3.1. Introduction and Epidemiology
6.3.3.2. Current Treatment Landscape
6.3.3.3. ADCs for Kidney Cancer
6.3.4. Ovarian Cancer
6.3.4.1. Introduction and Epidemiology
6.3.4.2. Current Treatment Landscape
6.3.4.3. ADCs for Ovarian Cancer
6.3.5. Breast Cancer
6.3.5.1. Introduction and Epidemiology
6.3.5.2. Current Treatment Landscape
6.3.5.3. ADCs for Breast Cancer
6.3.6. Glioblastoma
6.3.6.1. Introduction and Epidemiology
6.3.6.2. Current Treatment Landscape
6.3.6.3. ADCs for Glioblastoma
6.3.7. Lung Cancer
6.3.7.1. Introduction and Epidemiology
6.3.7.2. Current Treatment Landscape
6.3.7.3. ADCs for Lung Cancer
6.3.8. Colorectal Cancer
6.3.8.1. Introduction and Epidemiology
6.3.8.2. Current Market Landscape
6.3.8.3. ADCs for Colorectal Cancer
6.3.9. Prostate Cancer
6.3.9.1. Introduction and Epidemiology
6.3.9.2. Current Market Landscape
6.3.9.3. ADCs for Prostate Cancer
7. UPCOMING ADC DRUGS: DETAILED PROFILES AND MARKET FORECAST
7.1. Chapter Overview
7.2. Overall ADC Market Forecast, 2015 - 2025
7.2.1. Scope and Limitations
7.2.2. Forecast Methodology
7.2.3. ADC Drug Sales Market, 2015 - 2025
7.2.3.1. Overall Sales Forecast, 2015 - 2025: By Type of ADC
7.2.3.1. Overall Sales Forecast, 2015 - 2025: By Type of Linker
7.2.3.2. Overall Sales Forecast, 2015 - 2025: By Type of Cytotoxin
7.3. ADCETRIS®/ Brentuximab vedotin (Seattle Genetics / Millennium Pharmaceuticals)
7.3.1. Drug Overview
7.3.2. Mechanism of Action
7.3.3. Cost, Dosage and Reimbursement of ADCETRIS®
7.3.4. Factors Supporting the High Price
7.3.5. Clinical Development
7.3.6. Key Clinical Trial Results
7.3.7. ADCETRIS® Sales, 2011- H1 2015
7.3.8. Strategies for Market Expansion
7.3.9. ADCETRIS® Sales Forecast: Short-Midterm
7.3.10. ADCETRIS® Sales Forecast: Long Term
7.4. KADCYLA® / T-DM1 / RG3502 (Genentech / Roche)
7.4.1. Drug Overview
7.4.2. Mechanism of Action
7.4.3. Cost, Dosage and Reimbursement of KADCYLA®
7.4.4. Approval History
7.4.5. Clinical Development
7.4.6. KADCYLA® Sales, 2013 – H1, 2015
7.4.7. KADCYLA® Sales Forecast: Short-Midterm
7.4.8. KADCYLA® Sales Forecast: Long Term
7.5. CDX-011/ Glembatumumab Vedotin (Celldex Therapeutics)
7.5.1. Drug Overview
7.5.2. Mechanism of Action
7.5.3. Clinical Development
7.5.4. Key Clinical Trial Results
7.5.5. Competition for CDX-011
7.5.6. CDX-011 Sales Forecast: Long Term
7.6. RG7599/ Lifastuzumab Vedotin (Roche / Genentech)
7.6.1. Drug Overview
7.6.2. Mechanism of Action
7.6.3. Clinical Development
7.6.4. Key Clinical Trial Results
7.6.5. Competition For RG7599
7.6.6. RG7599 Sales Forecast: Long Term
7.7. BT-062 /Indatuximab Ravtansine (Biotest)
7.7.1. Drug Overview
7.7.2. Mechanism of Action
7.7.3. Clinical Development
7.7.4. Key Clinical Trial Results
7.7.5. Competition for BT-062
7.7.6. BT-062 Sales Forecast: Long Term
7.8. PSMA-ADC (Progenics Pharmaceuticals)
7.8.1. Drug Overview
7.8.2. Mechanism of Action
7.8.3. Clinical Development
7.8.4. Key Clinical Trial Results
7.8.5. Competition for PSMA ADC
7.8.6. PSMA ADC Sales Forecast: Long Term
7.9. MM-302 (Merrimack Pharmaceuticals)
7.9.1. Drug Overview
7.9.2. Mechanism of Action
7.9.3. Clinical Development
7.9.4. Key Clinical Trial Results
7.9.5. Competition for MM-302
7.9.6. MM-302 Sales Forecast: Long Term
7.10. IMMU-130 (Immunomedics)
7.10.1. Drug Overview
7.10.2. Mechanism of Action
7.10.3. Clinical Development
7.10.4. Key Clinical Trial Results
7.10.5. Competition for IMMU-130
7.10.6. IMMU-130 Sales Forecast: Long Term
7.11. CMC-544/ Inotuzumab Ozogamicin (Pfizer)
7.11.1. Drug Overview
7.11.2. Mechanism of Action
7.11.3. Clinical Development
7.11.4. Key Clinical Trial results
7.11.5. Competition for CMC-544
7.11.6. CMC-544 /Inotuzumab Ozogamicin Sales Forecast: Long Term, 2019-2025
7.12. RG7596/ Polatuzumab Vedotin (Roche)
7.12.1. Drug Overview
7.12.2. Mechanism of Action
7.12.3. Clinical Development
7.12.4. Key Clinical Trial Results
7.12.5. RG7596 Sales Forecast: Long Term
7.13. SAR3419/ Coltuximab Ravtansine (ImmunoGen)
7.13.1. Drug Overview
7.13.2. Mechanism of Action
7.13.3. Clinical Development
7.13.4. Key Clinical Trial Results
7.13.5. Competition for SAR3419
7.13.6. SAR3419 Sales Forecast: Long Term
7.14. ABT-414 (AbbVie)
7.14.1. Drug Overview
7.14.2. Mechanism of Action
7.14.3. Clinical Development
7.14.4. Key Clinical Trial Results
7.14.5. Competition for ABT-414
7.14.6. ABT-414 Sales Forecast: Long Term
7.15. Other Molecules
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.1.1. Type of Partnerships
8.1.2. Number of Partnerships have Increased Overtime
8.1.3. Seattle Genetics and ImmunoGen have been the Most Active Companies
9. VENTURE CAPITAL INTEREST
9.1. Chapter Overview
9.2. Instances of Funding in ADCs
9.3. Rising Venture Capital Interest
9.4. Funding Instances: Distribution by Type of Funding
9.5. Leading Players: Distribution by Number of Funding Instances
9.6. Most Active VC Firms/Institutions
10. COMPANY PROFILES
10.1. Chapter Overview
10.2. ImmunoGen
10.2.1. Company Overview
10.2.2. Financial Performance
10.2.3. ADC Pipeline
10.2.4. Collaborations
10.3. Seattle Genetics
10.3.1. Company Overview
10.3.2. Financial Performance
10.3.3. ADC Pipeline
10.3.4. Collaborations
10.4. Immunomedics
10.4.1. Company Overview
10.4.2. Financial Performance
10.4.3. ADC Pipeline
10.4.4. Collaborations
10.5. Pfizer
10.5.1. Company Overview
10.5.2. Financial Performance
10.5.3. ADC Pipeline
10.5.4. Collaborations
10.6. Roche / Genentech
10.6.1. Company Overview
10.6.2. Financial Performance
10.6.3. ADC Pipeline
10.6.4. Collaborations
10.7. Celldex Therapeutics
10.7.1. Company Overview
10.7.2. Financial Performance
10.7.3. ADC Pipeline
10.7.4. Collaborations
10.8. Millennium Pharmaceuticals
10.8.1. Company Overview
10.8.2. Financial Performance
10.8.3. ADC Pipeline
10.8.4. Collaborations
10.9. AbbVie
10.9.1. Company Overview
10.9.2. Financial Performance
10.9.3. ADC Pipeline
10.9.4. Recent Developments
10.9.5. Collaborations
10.11. Bayer HealthCare
10.11.1. Company Overview
10.11.2. Financial Performance
10.11.3. ADC Pipeline
10.11.4. Collaborations
10.12. Astellas Pharma/Agensys
10.12.1. Company Overview
10.12.2. Financial Performance
10.12.3. ADC Pipeline
10.12.4. Collaborations
10.13. Progenics Pharmaceuticals
10.13.1. Company Overview
10.13.2. Financial Performance
10.13.3. ADC Pipeline
10.13.4. Collaborations
10.14. Mersana Therapeutics
10.14.1. Company Overview
10.14.2. ADC Pipeline
10.14.3. Collaborations
10.15. Synthon
10.15.1. Company Overview
10.15.2. ADC Pipeline
10.15.3. Collaborations
10.16. Heidelberg Pharma
10.16.1. Company Overview
10.16.2. ADC Pipeline
10.16.3. Collaborations
10.17. Oxford BioTherapeutics
10.17.1. Company Overview
10.17.2. ADC Pipeline
10.17.3. Collaborations
11. CASE IN POINT: CONTRACT MANUFACTURING IN ADCs
11.1. Background
11.2. ADC Drugs: Limited Technology Providers
11.3. ADC Manufacturing: Key Steps
11.4. ADC Manufacturing: Key Challenges
11.5. In-House Manufacturing of ADCs
11.6. Global Presence of Contract Manufacturers
11.7. A Promising Scope For Investment
11.8. Emergence of Start-Ups
11.9. Contract Manufacturers Collaborating to Provide ADC Capabilities
11.10. CMOs Manufacturing Linkers
11.11. CMOs with HPAPI / Cytotoxic Capabilities
11.12. Growing Conjugation Capability
11.13. Full Service Providers for ADCs: An Unmet Need
12. SWOT ANALYSIS
12.1. Strengths
12.2. Weaknesses
12.3. Opportunities
12.4. Threats
13. INTERVIEW TRANSCRIPTS
13.1. Chapter Overview
13.2. Interview 1: Mark Wright, Site Head, Grangemouth, Piramal Healthcare
13.3. Interview 2: Christian Bailly, Head of CDMO, Pierre Fabre
13.4. Interview 3: Dr. John Burt, CEO, PolyTherics (an Abzena company)
13.5. Interview 4: Christian Rohlff, Founder & CEO, Oxford BioTherapeutics
13.6. Interview 5: Laurent Ducry, ADC R&D, Lonza
13.7. Interview 6: Stacy McDonald, Group Product Manager & Jennifer L. Mitcham, Director - Business Development, Catalent Pharma Solutions
13.8. Interview 7: Aldo Braca, CEO, BSP Pharmaceuticals
13.9. Interview 8: Director, Business Development, Anonymous CMO
13.10. Interview 9: Chief Executive Officer, Anonymous CMO
14. CONCLUSION
14.1. ADCETRIS® and KADCYLA®: The Current Flagbearers
14.2. Several Molecules Likely to Achieve Blockbuster Status
14.3. CMOs Expected to Play a Critical Role in Future Success
14.4. An Attractive Market for Large Pharmaceutical Companies; Start-ups Continue to Emerge
14.5. Collaborations Have Been Widespread; The Trend is Unlikely to Change
14.6. Concluding Remarks
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS
LIST OF FIGURES
Figure 3.1 Timeline of Cancer Treatments
Figure 3.2 Cancer Treatments: Type of Surgeries
Figure 3.3 Cancer Treatments: Type of Radiation Therapies
Figure 3.4 Cancer Treatments: Type of Chemotherapies
Figure 3.5 Components of ADC
Figure 4.1 ADC Clinical Pipeline: Distribution by Phases of Development
Figure 4.2 ADC Clinical Pipeline: Distribution by Indications
Figure 4.3 ADC Clinical Pipeline: Distribution by Linkers
Figure 4.4 ADC Clinical Pipeline: Distribution by Cytotoxins
Figure 4.5 ADC Clinical Pipeline: Distribution by Technology Providers
Figure 4.6 ADC Preclinical / Discovery Pipeline: Distribution by Phases of Development
Figure 4.7 ADC Preclinical Pipeline: Distribution by Indications
Figure 4.9 ADC Preclinical Pipeline: Distribution by Geographies
Figure 5.1 ADCETRIS®: Mapping Prominent Researchers
Figure 5.2 KADCYLA®: Mapping Prominent Researchers
Figure 5.3 Other ADCs: Mapping Prominent Researchers
Figure 5.4 ADC: Prominent Key Opinion Leaders
Figure 6.1 Most Common Types of Leukaemia
Figure 6.2 Leukaemia: Global Epidemiological Distribution
Figure 6.3 Lymphoma: Global Epidemiological Distribution
Figure 6.4 Multiple Myeloma: Global Epidemiological Distribution
Figure 6.5 Melanoma: Global Epidemiological Distribution
Figure 6.6 Bladder Cancer: Global Epidemiological Distribution
Figure 6.7 Kidney Cancer: Global Epidemiological Distribution
Figure 6.8 Ovarian Cancer: Global Epidemiological Distribution
Figure 6.9 Breast Cancer: Global Epidemiological Distribution
Figure 6.10 Lung Cancer: Types
Figure 6.11 Lung Cancer: Global Epidemiological Distribution
Figure 6.12 Colorectal Cancer: Global Epidemiological Distribution
Figure 6.13 Prostate Cancer: Global Epidemiological Distribution
Figure 7.1 ADC Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 7.2 ADC Sales Forecast, 2015 - 2025: By Type of ADC (USD Million)
Figure 7.3 ADC Sales Forecast, 2015 - 2025: By Type of Linker (USD Million)
Figure 7.4 ADC Sales Forecast, 2015 - 2025: By Type of Cytotoxin (USD Million)
Figure 7.5 ADCETRIS®: Registered Clinical Trials
Figure 7.6 ADCETRIS® Sales: 2011 – H1, 2015 (USD Million)
Figure 7.7 ADCETRIS® Market (USD Million), Short-Midterm Forecast: (Base Scenario)
Figure 7.8 ADCETRIS® Market (USD Million), Long Term Forecast: (Base Scenario)
Figure 7.9 KADCYLA®: Registered Clinical Trials
Figure 7.10 KADCYLA® Sales, 2013 – H1, 2015 (CHF Million)
Figure 7.11 KADCYLA® / T-DM1 Market (USD Million), Short-Midterm Forecast: (Base Scenario)
Figure 7.12 KADCYLA® / T-DM1 Market (USD Million), Long Term Forecast: (Base Scenario)
Figure 7.13 CDX-011: Registered Clinical Trials
Figure 7.14 CDX-011/ Glembatumumab Vedotin Market (USD Million), Long Term Forecast: (Base Scenario)
Figure 7.15 RG7599: Registered Clinical Trials
Figure 7.16 RG7599 Market (USD Million), Long Term Forecast: (Base Scenario)
Figure 7.17 BT-062 Market (USD Million), Long Term Forecast: (Base Scenario)
Figure 7.18 PSMA-ADC: Registered Clinical Trials
Figure 7.19 PSMA ADC Market (USD Million), Long Term Forecast: (Base Scenario)
Figure 7.20 MM-302 Market (USD Million), Long Term Forecast: (Base Scenario)
Figure 7.21 IMMU-130: Registered Clinical trials
Figure 7.22 IMMU-130 Market (USD Million), Long Term Forecast: (Base Scenario)
Figure 7.23 CMC-544: Registered Clinical Trials
Figure 7.24 CMC-544/ Inotuzumab Ozogamicin Market (USD Million), Long Term Forecast: (Base Scenario)
Figure 7.25 RG7596: Registered Clinical Trials
Figure 7.26 RG7596 Market (USD Million), Long Term Forecast: (Base Scenario)
Figure 7.27 SAR3419: Registered Clinical Trials
Figure 7.28 SAR3419 Market (USD Million), Long Term Forecast: (Base Scenario)
Figure 7.29 ABT-414 Market (USD Million), Long Term Forecast: (Base Scenario)
Figure 7.30 BAY94-9343 Market (USD Million), Long Term Forecast: (Base Scenario)
Figure 7.31 IMMU-132 Market (USD Million), Long Term Forecast: (Base Scenario)
Figure 8.1 ADC: Partnerships, 2005 - 2015
Figure 8.2 ADC Partnerships: Major Stakeholders
Figure 9.1 Cumulative Funding Instances, Pre 2005 - 2015
Figure 9.2 Funding Instances: Total Amount Invested Annually (USD Million)
Figure 9.3 Funding Instances: Distribution by Type, Pre 2005 - 2015
Figure 9.4 Funding Instances: Distribution by Total Amount Invested, (USD Million)
Figure 9.5 Most Active Players: Distribution by Number of Funding Instances
Figure 9.6 Most Active VC Firms: Evaluation by Number of Instances
Figure 10.1 ImmunoGen: Revenues (USD Million), 2011 – 2015
Figure 10.2 Seattle Genetics: Revenues (USD Million), 2010 - H1 2015
Figure 10.3 Immunomedics: Revenues (USD Million), 2011 – 2015
Figure 10.4 Pfizer: Revenues (USD Billion), 2010 – H1, 2015
Figure 10.5 Roche: Revenues (CHF Billion), 2011 – H1, 2015
Figure 10.6 Roche: Segment Sales (CHF Billion), 2010 – H1, 2015
Figure 10.7 Celldex Therapeutics: Revenues (USD Million), 2010 - H1, 2015
Figure 10.8 Takeda Pharmaceuticals: Revenues (JPY Billion), 2010 - 2014
Figure 10.9 AbbVie: Revenues (USD Billion), 2010 - Q3, 2015
Figure 10.10 Bayer HealthCare: Revenues (EUR Billion), 2010 - Q3, 2015
Figure 10.11 Astellas Pharma: Revenues (JPY Billion), 2011 - 2015
Figure 10.12 Progenics Pharmaceuticals: Revenues (USD Million), 2010 – 2014
Figure 11.1 ADC Market Forecast (USD Million): 2015, 2020 and 2025
LIST OF TABLES
Table 3.1 FDA Approved Antibody Based Therapeutics for Cancer
Table 3.2 Commonly Used Cytotoxins for ADC Therapeutics
Table 3.3 OEL Bands, Safebridge Consultants
Table 4.1 ADCs: Marketed and Development Pipeline
Table 4.2 ADCs: Preclinical Pipeline
Table 5.1 ADCs: Principal Investigators
Table 6.1 Comparison of HL and NHL
Table 6.2 Comparison of Marketed Targeted Therapeutics: Leukaemia
Table 6.3 Comparison of Marketed Targeted Therapeutics: Lymphoma
Table 6.4 ADCs for Leukaemia and Lymphoma
Table 6.5 Comparison of Marketed Targeted Therapeutics: Multiple Myeloma
Table 6.6 ADCs for Multiple Myeloma
Table 6.7 Comparison of Marketed Targeted Therapeutics: Melanoma
Table 6.8 ADCs for Metastatic Melanoma
Table 6.9 ADCs for Bladder Cancer
Table 6.10 Comparison of Marketed Targeted Therapeutics: RCC
Table 6.11 ADCs for Kidney Cancer
Table 6.12 ADCs for Ovarian Cancer
Table 6.13 Comparison of Marketed Therapeutics: Breast Cancer
Table 6.14 ADCs for Breast Cancer
Table 6.15 ADCs for Glioblastoma
Table 6.16 Comparison of Marketed Therapeutics: Lung Cancer
Table 6.17 ADCs for Lung Cancer
Table 6.18 Comparison of Marketed Therapeutics: Colorectal Cancer
Table 6.19 ADCs for Colorectal Cancer
Table 6.20 Comparison of Marketed Therapeutics: Prostate Cancer
Table 6.21 ADCs for Prostate Cancer
Table 7.1 ADCs: Marketed/ Late Stage Molecules
Table 7.2 ADCETRIS®/ Brentuximab vedotin: Ongoing Clinical Trials
Table 7.3 KADCYLA® / T-DM1: Ongoing Clinical Trials
Table 7.4 CDX-011/ Glembatumumab Vedotin: Ongoing Clinical Trials
Table 7.5 RG7599/ Lifastuzumab Vedotin: Ongoing Clinical Trials
Table 7.6 BT-062: Ongoing Clinical Trials
Table 7.7 Comparison of Drugs Available for Metastatic Castration Resistant Prostate Cancer
Table 7.8 MM-302: Ongoing Clinical Trials
Table 7.9 IMMU-130: Ongoing Clinical Trials
Table 7.10 CMC-544/ Inotuzumab Ozogamicin: Ongoing Clinical Trials
Table 7.11 RG7596/ Polatuzumab Vedotin: Ongoing Clinical Trials
Table 7.12 SAR3419/ Coltuximab Ravtansine: Ongoing Clinical Trials
Table 7.13 ABT-414: Ongoing Clinical Trials
Table 8.1 List of Partnerships in the Field of ADCs, 2000 - 2015
Table 9.1 List of Funding Instances in ADCs
Table 9.2 Types of Funding Instances, 1998-2015
Table 10.1 ImmunoGen ADC Pipeline, 2015
Table 10.2 Seattle Genetics ADC Pipeline, 2015
Table 10.3 Immunomedics ADC Pipeline, 2015
Table 10.4 Pfizer / Wyeth ADC Pipeline, 2015
Table 10.5 Roche / Genentech ADC Pipeline, 2015
Table 10.6 Celldex Therapeutics ADC Pipeline, 2015
Table 10.7 Millennium Pharmaceuticals ADC Pipeline, 2015
Table 10.8 AbbVie ADC Pipeline, 2015
Table 10.9 Bayer HealthCare ADC Pipeline, 2015
Table 10.12 Mersana Therapeutics ADC Pipeline, 2015
Table 11.1 List of Contract Manufacturers and Their Capabilities in ADC Manufacturing
Table 11.2 CMOs Offering ADC Conjugation Services
Table 11.3 Full Service Contract Manufacturers for ADCs
Table 9.1 SWOT Analysis
Table 15.1 ADC Clinical Pipeline: Distribution by Phases of Development
Table 15.2 ADC Clinical Pipeline: Distribution by Indications
Table 15.3 ADC Clinical Pipeline: Distribution by Linkers
Table 15.4 ADC Clinical Pipeline: Distribution by Cytotoxins
Table 15.5 ADC Clinical Pipeline: Distribution by Technology Developers
Table 15.6 ADC Preclinical / Discovery Pipeline: Distribution by Phases of Development
Table 15.7 ADC Preclinical / Discovery Pipeline: Distribution by Indications
Table 15.8 ADC Preclinical / Discovery Pipeline: Distribution by Geographies
Table 15.9 ADC Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.10 ADC Sales Market Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.11 ADC Sales Market Forecast, 2015-2025: Optimistic Scenario (USD Million)
Table 15.12 ADC Sales Forecast by Type of ADCs, 2015-2025: Conservative Scenario (USD Million)
Table 15.13 ADC Sales Forecast by Type of ADCs 2015-2025: Base Scenario (USD Million)
Table 15.14 ADC Sales Forecast by Type of ADCs 2015-2025: Optimistic Scenario (USD Million)
Table 15.15 ADC Sales Forecast by Type of Cytotoxin (2015-2025): Conservative Scenario (USD Million)
Table 15.16 ADC Sales Forecast by Type of Cytotoxin (2015-2025): Base Scenario (USD Million)
Table 15.17 ADC Sales Forecast by Type of Cytotoxin (2015-2025): Optimistic Scenario (USD Million)
Table 15.18 ADC Sales Forecast by Type of Linker (2015-2025): Conservative Scenario (USD Million)
Table 15.19 ADC Sales Forecast by Type of Linker (2015-2025): Base Scenario (USD Million)
Table 15.20 ADC Sales Forecast by Type of Linker (2015-2025): Optimistic Scenario (USD Million)
Table 15.21 ADCETRIS®: Registered Clinical Trials
Table 15.22 ADCETRIS® Market (USD Million), Short-Midterm Forecast: Conservative Scenario
Table 15.23 ADCETRIS® Market (USD Million), Short-Midterm Forecast: Base Scenario
Table 15.24 ADCETRIS® Market (USD Million), Short-Midterm Forecast: Optimistic Scenario
Table 15.25 ADCETRIS® Market (USD Million), Long Term Forecast: Conservative Scenario
Table 15.26 ADCETRIS® Market (USD Million), Long Term Forecast: Base Scenario
Table 15.27 ADCETRIS® Market (USD Million), Long Term Forecast: Optimistic Scenario
Table 15.28 KADCYLA®: Registered Clinical Trials
Table 15.29 KADCYLA® / T-DM1 Market (USD Million), Short-Midterm Forecast: Conservative Scenario
Table 15.30 KADCYLA® / T-DM1 Market (USD Million), Short-Midterm Forecast: Base Scenario
Table 15.31 KADCYLA® / T-DM1 Market (USD Million), Short-Midterm Forecast: Optimistic Scenario
Table 15.32 KADCYLA® / T-DM1 Market (USD Million), Long Term Forecast: Conservative Scenario
Table 15.33 KADCYLA® / T-DM1 Market (USD Million), Long Term Forecast: Base Scenario
Table 15.34 KADCYLA® / T-DM1 Market (USD Million), Long Term Forecast: Optimistic Scenario
Table 15.35 CDX-011: Registered Clinical Trials
Table 15.36 CDX-011 Market (USD Million), Long Term Forecast: Conservative Scenario
Table 15.37 CDX-011 Market (USD Million), Long Term Forecast: Base Scenario
Table 15.38 CDX-011 Market (USD Million), Long Term Forecast: Optimistic Scenario
Table 15.39 RG7599: Registered Clinical Trials
Table 15.40 RG7599 Market (USD Million), Long Term Forecast: Conservative Scenario
Table 15.41 RG7599 Market (USD Million), Long Term Forecast: Base Scenario
Table 15.42 RG7599 Market (USD Million), Long Term Forecast: Optimistic Scenario
Table 15.43 BT-062 Market (USD Million), Long Term Forecast: Conservative Scenario
Table 15.44 BT-062 Market (USD Million), Long Term Forecast: Base Scenario
Table 15.45 BT-062 Market (USD Million), Long Term Forecast: Optimistic Scenario
Table 15.46 PSMA ADC: Registered Clinical Trials
Table 15.47 PSMA ADC Market (USD Million), Long Term Forecast: Conservative Scenario
Table 15.48 PSMA ADC Market (USD Million), Long Term Forecast: Base Scenario
Table 15.49 PSMA ADC Market (USD Million), Long Term Forecast: Optimistic Scenario
Table 15.50 MM-302 Market (USD Million), Long Term Forecast: Conservative Scenario
Table 15.51 MM-302 Market (USD Million), Long Term Forecast: Base Scenario
Table 15.52 MM-302 Market (USD Million), Long Term Forecast: Optimistic Scenario
Table 15.53 IMMU-130: Registered Clinical Trials
Table 15.54 IMMU-130 Market (USD Million), Long Term Forecast: Conservative Scenario
Table 15.55 IMMU-130 Market (USD Million), Long Term Forecast: Base Scenario
Table 15.56 IMMU-130 Market (USD Million), Long Term Forecast: Optimistic Scenario
Table 15.57 CMC-544: Registered Clinical Trials
Table 15.58 CMC-544 Market (USD Million), Long Term Forecast: Conservative Scenario
Table 15.59 CMC-544 Market (USD Million), Long Term Forecast: Base Scenario
Table 15.60 CMC-544 Market (USD Million), Long Term Forecast: Optimistic Scenario
Table 15.61 RG7596: Registered Clinical Trials
Table 15.62 RG7596 Market (USD Million), Long Term Forecast: Conservative Scenario
Table 15.63 RG7596 Market (USD Million), Long Term Forecast: Base Scenario
Table 15.64 RG7596 Market (USD Million), Long Term Forecast: Optimistic Scenario
Table 15.65 SAR 3419: Registered Clinical Trials
Table 15.66 SAR 3419 Market (USD Million), Long Term Forecast: Conservative Scenario
Table 15.67 SAR 3419 Market (USD Million), Long Term Forecast: Base Scenario
Table 15.57 SAR 3419 Market (USD Million), Long Term Forecast: Optimistic Scenario
Table 15.69 ABT-414 Market (USD Million), Long Term Forecast: Conservative Scenario
Table 15.70 ABT-414 Market (USD Million), Long Term Forecast: Base Scenario
Table 15.71 ABT-414 Market (USD Million), Long Term Forecast: Optimistic Scenario
Table 15.72 BAY949343 Market (USD Million), Long Term Forecast: Conservative Scenario
Table 15.73 BAY949343 Market (USD Million), Long Term Forecast: Base Scenario
Table 15.74 BAY949343 Market (USD Million), Long Term Forecast: Optimistic Scenario
Table 15.75 IMMU132 Market (USD Million), Long Term Forecast: Conservative Scenario
Table 15.76 IMMU132 Market (USD Million), Long Term Forecast: Base Scenario
Table 15.77 IMMU132 Market (USD Million), Long Term Forecast: Optimistic Scenario
Table 15.78 ADC: Partnerships, 2005-2015
Table 15.79 ADC Partnerships: Major Stakeholders
Table 15.80 Funding: Cumulative Number of Investments by Year, 1998-2015
Table 15.81 Funding Instances: Total Amount Invested Annually (USD Million)
Table 15.82 Funding Instances: Distribution by Type, 1998-2015
Table 15.83 Funding Instances: Distribution by Total Amount Invested, 1998-2015
Table 15.84 Most Active Players: Distribution by Number Funding Instances
Table 15.85 Most Active VC Firms: Evaluation by Number Funding Instances
Table 15.86 ImmunoGen: Revenues (USD Million), 2011-2015
Table 15.87 Seattle Genetics: Revenues (USD Million), 2010-H1, 2015
Table 15.88 Immunomedics: Revenues (USD Million), 2011- 2015
Table 15.89 Pfizer: Revenues (USD Billion), 2010- H1, 2015
Table 15.90 Roche: Revenues (CHF Billion), 2010- H1, 2015
Table 15.91 Roche: Segment Revenues (CHF Billion), 2010-H1, 2015
Table 15.92 Celldex Therapeutics: Revenues (USD Billion), 2010- H1, 2015
Table 15.93 Takeda Pharmaceuticals (JPY Billion): Revenues, 2010- 2014
Table 15.94 AbbVie: Revenues (USD Billion), 2010- Q3, 2015
Table 15.95 Bayer HealthCare: Revenues (EUR Billion), 2010- Q3, 2015
Table 15.96 Astellas Pharma: Revenues (JPY Billion), 2011- 2015
Table 15.97 Progenics Pharmaceuticals: Revenues (USD Million), 2010- 2014
Table 15.98 ADC Market Forecast (USD Million): 2015, 2020, 2025

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report